CH455148A - Verfahren zur Vermehrung des Tollwutvirus - Google Patents
Verfahren zur Vermehrung des TollwutvirusInfo
- Publication number
- CH455148A CH455148A CH961363A CH961363A CH455148A CH 455148 A CH455148 A CH 455148A CH 961363 A CH961363 A CH 961363A CH 961363 A CH961363 A CH 961363A CH 455148 A CH455148 A CH 455148A
- Authority
- CH
- Switzerland
- Prior art keywords
- rabies virus
- virus
- chicken embryo
- passages
- culture
- Prior art date
Links
- 241000711798 Rabies lyssavirus Species 0.000 title claims description 33
- 238000000034 method Methods 0.000 title claims description 32
- 239000002609 medium Substances 0.000 claims description 33
- 241000287828 Gallus gallus Species 0.000 claims description 31
- 210000001161 mammalian embryo Anatomy 0.000 claims description 29
- 238000010790 dilution Methods 0.000 claims description 26
- 239000012895 dilution Substances 0.000 claims description 26
- 235000013601 eggs Nutrition 0.000 claims description 13
- 238000012423 maintenance Methods 0.000 claims description 12
- 238000011081 inoculation Methods 0.000 claims description 11
- 235000015097 nutrients Nutrition 0.000 claims description 11
- 230000000644 propagated effect Effects 0.000 claims description 8
- 238000004140 cleaning Methods 0.000 claims description 4
- 239000002356 single layer Substances 0.000 claims description 4
- 238000002255 vaccination Methods 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 241000700605 Viruses Species 0.000 description 48
- 210000001519 tissue Anatomy 0.000 description 28
- 235000013330 chicken meat Nutrition 0.000 description 24
- 229960005486 vaccine Drugs 0.000 description 24
- 230000012010 growth Effects 0.000 description 10
- 241000700198 Cavia Species 0.000 description 9
- 210000003837 chick embryo Anatomy 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- 239000002054 inoculum Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 150000001447 alkali salts Chemical class 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 102000004407 Lactalbumin Human genes 0.000 description 2
- 108090000942 Lactalbumin Proteins 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 201000006509 pleuropneumonia Diseases 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 229940124974 vaccine stabilizer Drugs 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US214854A US3255080A (en) | 1962-08-06 | 1962-08-06 | Live rabies virus vaccine and method for the production thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH455148A true CH455148A (de) | 1968-04-30 |
Family
ID=22800666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH961363A CH455148A (de) | 1962-08-06 | 1963-08-02 | Verfahren zur Vermehrung des Tollwutvirus |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US3255080A (en:Method) |
| CH (1) | CH455148A (en:Method) |
| DK (1) | DK105426C (en:Method) |
| FR (1) | FR3839M (en:Method) |
| GB (1) | GB1001689A (en:Method) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4021302A (en) * | 1966-02-18 | 1977-05-03 | Burroughs Wellcome & Co., Inc. | Cell cultures |
| US3674862A (en) * | 1970-04-02 | 1972-07-04 | Lilly Co Eli | Live attenuated rabies virus vaccine and process therefor |
| GB1596653A (en) * | 1977-01-26 | 1981-08-26 | Gist Brocades Nv | Vaccine |
| CH638985A5 (de) * | 1979-04-10 | 1983-10-31 | Schweiz Serum & Impfinst | Verfahren zur herstellung eines tollwutimpfstoffes und danach erhaltener impfstoff. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2768114A (en) * | 1953-08-21 | 1956-10-23 | American Cyanamid Co | Rabies vaccines and methods of preparing the same |
| US2965544A (en) * | 1959-02-24 | 1960-12-20 | American Cyanamid Co | Tissue culture propagated canine distemper virus and vaccine thereof |
| US3080291A (en) * | 1960-06-10 | 1963-03-05 | Jensen Salsberg Lab Inc | Serial passage of distemper virus in tissue cultures of chick embryo and canine tissue and vaccine therefrom |
| US3143470A (en) * | 1961-04-24 | 1964-08-04 | Parke Davis & Co | Rabies virus propagation in embryonic cells maintained in a medium containing pancreatic digest of casein |
-
1962
- 1962-08-06 US US214854A patent/US3255080A/en not_active Expired - Lifetime
-
1963
- 1963-07-15 GB GB27896/63A patent/GB1001689A/en not_active Expired
- 1963-08-02 CH CH961363A patent/CH455148A/de unknown
- 1963-08-05 DK DK373863AA patent/DK105426C/da active
- 1963-10-31 FR FR952517A patent/FR3839M/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR3839M (en:Method) | 1966-01-17 |
| DK105426C (da) | 1966-09-26 |
| GB1001689A (en) | 1965-08-18 |
| US3255080A (en) | 1966-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69327307T2 (de) | Herstellung von antigenen und impfstoffen vom mysterie-disease-virus, antigene und erworbene impfstoffe zur verhinderung dieser krankheit | |
| DE2851928C2 (en:Method) | ||
| DE1617940C2 (de) | Verfahren zur Gewinnung eines für die Züchtung von Viren geeigneten Zellstammes | |
| DE1957747A1 (de) | Impfstoffe und Verfahren zu ihrer Herstellung | |
| EP0019218A2 (de) | Influenzavirus-Vaccine, Verfahren zu ihrer Herstellung und Verfahren zur Vermehrung von Influenzaviren | |
| DE2828073C2 (de) | Verfahren zum Kultivieren von Viren | |
| CH658192A5 (de) | Tollwut-impfstoff und verfahren zu seiner herstellung. | |
| CH455148A (de) | Verfahren zur Vermehrung des Tollwutvirus | |
| DE1198489B (de) | Verfahren zur Herstellung eines Impfstoffes gegen Panleucopenie | |
| AT243435B (de) | Verfahren zur Herstellung einer Tollwutvakzine | |
| DE2058645C2 (de) | Verfahren zur Herstellung eines stark abgeschwächten Newcastle-Disease-Virus-Lebendimpfstoffs | |
| CH423095A (de) | Verfahren zur Herstellung eines Tollwutimpfstoffes | |
| US4252792A (en) | Injectable rabies vaccine composition and method for preparing same | |
| DE3878982T2 (de) | Abgeschwaechtes virus und impfstoffe davon zur verwendung gegen infektionen bei gefluegel, verursacht durch truthahn-rhinotracheitis-virus. | |
| DE1176317B (de) | Verfahren zur Herstellung von fuer Impf-zwecke geeigneten waessrigen Fluessigkeiten mit Tollwut-Virus | |
| DE1492243C3 (de) | Injizierbare Impfstoffe | |
| DE2162013C3 (de) | Tollwut-Lebendimpfstoff, Verfahren zu seiner Herstellung nd seine Verwendung bei der Bekämpfung von Tollwut | |
| EP0158285B1 (de) | Verfahren zur Gewinnung von Zellkulturen | |
| EP0049296B1 (en) | Injectable rabies vaccine composition and method for preparing same | |
| DE3136430C2 (en:Method) | ||
| JPS62275680A (ja) | 家禽の伝染性気管支炎ウイルス株 | |
| DE908909C (de) | Verfahren zur Herstellung und Verarbeitung pathogener Viren und der sie begleitenden Stoffe | |
| CA1154673A (en) | Injectable rabies vaccine composition and method for preparing same | |
| DE2121237C3 (de) | Verwendung einer Zellinie zur Züchtung von Viren | |
| Miller et al. | The sterilization and preliminary attempts in the axenic cultivation of the black planarian Dugesia orotocephala |